NEO · Neogenomics Inc
$18.69
+0.33 (+1.77%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$2.48B
Shares
128.48M
Volume · Oct 1
322.57K
Avg daily vol (3M)
2.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.36
Open$18.76
Day$18.28–18.97
52W close$7.19–19.91
Avg vol 30d2.0M
Short int16.7M · 13.0% float · 11.2d
Short vol38%
Last earningsJul 28, 2026
DataJan 2020–Sep 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 4 wks
filed Jul 28, 2026
call held Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$766.29M
Trailing 12 months
Net income (TTM)
−$51.88M
Trailing 12 months
Revenue growth YoY
+11.2%
Year over year
Operating margin
-8.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.3%
Year over year · more shares
Price change (1Y)
+137.8%
Trailing year
Short interest
13.0%
Latest settlement · 11.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+50%
above
Price vs 50-day avg
+8%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
88%
near high
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+131%
trailing
YTD return
+56%
this year
Relative strength
+119%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$321.4K over 90 days · 100% sells
Short interest
Rising
13.01% of float · ▲ +6.0% MoM · 11.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
269 holders — mid 3-yr range
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
43%
contracting
EPS growth
−300%
Y/Y
Free cash flow
$-21.8M
Balance sheet
$195.7M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Full year 26 revenue
· full year 2026
Initiated
$802M – $806M
prior FY $727.33M
midpoint +10.5% Y/Y
Guided vs delivered
· last 3 settled
Revenue
full year
guided $530M – $550M
$509.73M
Miss −5.6%
Revenue
Q1
guided $118M – $120M
$117.17M
Miss −1.5%
Consolidated revenue
full-year 2021
guided $482.5M – $487.5M
$484.33M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+50%
Bullish
Price vs 50-day avg
+8%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
88%
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$321.4K over 90 days · 100% sells
Short interest
Rising
13.01% of float · ▲ +6.0% MoM · 11.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
269 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $18 · 88%
Range high $20
vs 200-day avg +50%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $14.47M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEO
this stock
Neogenomics Inc
|
$2.48B | +56.1% | +10.1% | — | 13.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEO | +0.0% | +5.2% | +131.2% | +2.5% | +56.1% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +0.7% | +5.1% | +119.1% | +3.1% | +44.3% |